Iovance Biotherapeutics Inc
IOVA1.750USD
-1.420-44.79%
收盘 05/09, 16:00（美东）报价延迟15分钟
534.19M总市值
亏损市盈率 TTM
关于 Iovance Biotherapeutics Inc 公司
Iovance Biotherapeutics, Inc. 是一家临床阶段的生物制药公司。该公司开发并提供针对实体瘤癌症患者的肿瘤浸润淋巴细胞 (TIL) 疗法。其主要候选产品 Amtagvi (lifileucel) 是一种肿瘤衍生的自体 T 细胞免疫疗法，用于治疗之前用 PD-1 阻断抗体治疗的不可切除或转移性黑色素瘤成年患者，如果 BRAF V600 突变阳性，则使用 BRAF 抑制剂（含或不含 MEK 抑制剂）。该公司还销售用于 Amtagvi 治疗方案的 Proleukin (aldesleukin)，一种白细胞介素-2 或 IL-2 产品。其开发渠道包括在实体瘤癌症的其他治疗环境中对 TIL 细胞疗法进行多中心试验。Amtagvi 和 Proleukin 是治疗方案的一部分，该方案还包括淋巴细胞清除。该公司还在开发使用 TIL 的下一代疗法，例如转基因 TIL 细胞疗法。
公司简介
公司代码IOVA
公司名称Iovance Biotherapeutics Inc
上市日期Jun 20, 2008
成立日期2017
CEODr. Frederick G. Vogt, J.D., Ph.D.
员工数量838
证券类型Ordinary Share
年结日Jun 20
公司地址825 Industrial Road
城市SAN CARLOS
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编94070
电话16502607120
网址https://www.iovance.com/
公司代码IOVA
上市日期Jun 20, 2008
成立日期2017
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Frederick G. Vogt, J.D., Ph.D.
Dr. Frederick G. Vogt, J.D., Ph.D.
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
349.65K
+3.55%
Dr. Michael Weiser, M.D., Ph.D.
Dr. Michael Weiser, M.D., Ph.D.
Independent Director
Independent Director
112.63K
--
Dr. Igor P. Bilinsky, Ph.D.
Dr. Igor P. Bilinsky, Ph.D.
Chief Operating Officer
Chief Operating Officer
87.58K
+1.61%
Mr. Jean-Marc Bellemin
Mr. Jean-Marc Bellemin
Chief Financial Officer
Chief Financial Officer
56.20K
-8.97%
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.00K
--
Mr. Ryan D. Maynard
Mr. Ryan D. Maynard
Independent Director
Independent Director
7.50K
--
Dr. Raj K Puri, M.D., Ph.D.
Dr. Raj K Puri, M.D., Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
--
--
Mr. Wayne P. Rothbaum
Mr. Wayne P. Rothbaum
Independent Director
Independent Director
--
--
Mr. Daniel Gordon (Dan) Kirby
Mr. Daniel Gordon (Dan) Kirby
Chief Commercial Officer
Chief Commercial Officer
--
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Frederick G. Vogt, J.D., Ph.D.
Dr. Frederick G. Vogt, J.D., Ph.D.
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
349.65K
+3.55%
Dr. Michael Weiser, M.D., Ph.D.
Dr. Michael Weiser, M.D., Ph.D.
Independent Director
Independent Director
112.63K
--
Dr. Igor P. Bilinsky, Ph.D.
Dr. Igor P. Bilinsky, Ph.D.
Chief Operating Officer
Chief Operating Officer
87.58K
+1.61%
Mr. Jean-Marc Bellemin
Mr. Jean-Marc Bellemin
Chief Financial Officer
Chief Financial Officer
56.20K
-8.97%
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.00K
--
Mr. Ryan D. Maynard
Mr. Ryan D. Maynard
Independent Director
Independent Director
7.50K
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月4日 周日
更新时间: 5月4日 周日
持股股东
股东类型
持股股东
股东统计
占比
Quogue Capital L.L.C.
8.40%
The Vanguard Group, Inc.
8.23%
MHR Fund Management LLC
7.31%
Perceptive Advisors LLC
6.62%
BlackRock Institutional Trust Company, N.A.
6.15%
Other
63.28%
持股股东
股东统计
占比
Quogue Capital L.L.C.
8.40%
The Vanguard Group, Inc.
8.23%
MHR Fund Management LLC
7.31%
Perceptive Advisors LLC
6.62%
BlackRock Institutional Trust Company, N.A.
6.15%
Other
63.28%
股东类型
股东统计
占比
Investment Advisor
24.77%
Investment Advisor/Hedge Fund
21.77%
Private Equity
13.95%
Hedge Fund
8.74%
Venture Capital
8.50%
Research Firm
3.25%
Bank and Trust
0.70%
Pension Fund
0.54%
Individual Investor
0.31%
Other
17.47%
机构持股
更新时间: 3月4日 周二
更新时间: 3月4日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q1
658
278.41M
85.05%
-24.34M
2024Q4
654
278.66M
85.07%
-21.74M
2024Q3
641
272.75M
89.13%
-24.76M
2024Q2
630
269.09M
94.68%
-12.01M
2024Q1
622
253.92M
89.61%
-22.91M
2023Q4
605
240.15M
93.91%
-35.32M
2023Q3
601
248.03M
97.72%
-14.72M
2023Q2
594
232.36M
107.55%
-14.37M
2023Q1
607
232.93M
108.05%
+12.27M
2022Q4
639
197.16M
124.92%
+7.22M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Quogue Capital L.L.C.
28.07M
8.56%
+5.00M
+21.68%
Feb 20, 2024
The Vanguard Group, Inc.
27.48M
8.38%
+210.50K
+0.77%
Dec 31, 2024
MHR Fund Management LLC
24.42M
7.45%
+420.00K
+1.75%
Dec 31, 2024
Perceptive Advisors LLC
22.11M
6.74%
-4.51M
-16.93%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
20.17M
6.15%
+1.46M
+7.80%
Dec 31, 2024
State Street Global Advisors (US)
12.25M
3.74%
-952.70K
-7.22%
Dec 31, 2024
Hood River Capital Management LLC
8.99M
2.74%
+846.94K
+10.40%
Dec 31, 2024
Soleus Capital Management, L.P.
6.56M
2%
-1.97M
-23.08%
Dec 31, 2024
Geode Capital Management, L.L.C.
5.87M
1.79%
+222.43K
+3.94%
Dec 31, 2024
T. Rowe Price Investment Management, Inc.
5.83M
1.78%
-26.82K
-0.46%
Dec 31, 2024
查看更多
持股ETF
更新时间: 5月6日 周二
更新时间: 5月6日 周二
机构名称
占比
iShares Genomics Immunology and Healthcare ETF
1.21%
WisdomTree BioRevolution Fund
0.76%
Virtus LifeSci Biotech Products ETF
0.69%
Range Cancer Immunotherapy ETF
0.6%
SPDR S&P Biotech ETF
0.29%
Direxion Daily S&P Biotech Bull 3X Shares
0.18%
ProShares Ultra Nasdaq Biotechnology
0.11%
Invesco Nasdaq Biotechnology ETF
0.11%
iShares Biotechnology ETF
0.08%
Strive Small-Cap ETF
0.06%
查看更多
iShares Genomics Immunology and Healthcare ETF
占比1.21%
WisdomTree BioRevolution Fund
占比0.76%
Virtus LifeSci Biotech Products ETF
占比0.69%
Range Cancer Immunotherapy ETF
占比0.6%
SPDR S&P Biotech ETF
占比0.29%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.18%
ProShares Ultra Nasdaq Biotechnology
占比0.11%
Invesco Nasdaq Biotechnology ETF
占比0.11%
iShares Biotechnology ETF
占比0.08%
Strive Small-Cap ETF
占比0.06%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据